Genetic behind brain disease that can cause vertigo discovered

Publicly released:
Australia; WA

The genetic cause of a brain disease that leads to vertigo, speech difficulties and loss of coordination, and which can leave patients dependent on wheelchairs, has evaded scientists for decades. However, geneticists from Canada, the USA, Germany, India and Australia have found a genetic link that explains a large percentage of the undiagnosed adult-onset neurodegenerative disease, Cerebellar Ataxia.

Media release

From: Harry Perkins Institute of Medical Research

The genetic cause of a brain disease that leads to vertigo, speech difficulties and loss of coordination, and which can leave patients dependent on wheelchairs, has evaded scientists for decades.

However, geneticists from Canada, the USA, Germany, India and Australia have found a genetic link that explains a large percentage of the undiagnosed adult-onset neurodegenerative disease, Cerebellar Ataxia.

The mutation, which is similar to the type that triggers Huntington’s disease, causes a significant proportion of currently unsolved adult-onset ataxia, a term that describes poor muscle control.

The Perth team involved in the international collaboration was led by Associate Professor Gina Ravenscroft at the Harry Perkins Institute of Medical Research (Perkins).

“This discovery will likely lead to an accurate genetic diagnosis for many patients and families who do not know what is causing their challenging, life affecting symptoms. It is also likely other genetically undiagnosed ataxia patients will have other, yet to be found, similar mutations,” she said.

Clinical lead in the research, Professor Phillipa Lamont at Royal Perth Hospital says patients long to know what it is they are suffering from.

“Finding the cause of a patient’s disease is very important for several reasons. An accurate diagnosis gives the patient an assurance that some more treatable cause is not being missed.

“They also can be advised what the future may hold for them and make plans. It allows them to have reproductive choices if they are of child-bearing age, and although there is no treatment for this condition at the moment, all the treatments we have for other genetic diseases that are emerging rely completely on knowing exactly what genetic change has caused the disease,” Professor Lamont said.

Triggers for disease episodes in people with the genetic mutation include alcohol and exercise. For some patients, exercise can temporarily worsen their poor balance and increase their risk of falls.

Patient, Leslie Kelly (69) a trainer in gold processing plants had to leave the workforce after experiencing falls which fractured his spine and broke his wrist.

“I found it very hard to settle into retirement at a young age, but I couldn’t get work, no insurer would insure me because of my loss of balance,” he said.

Professor Lamont says “patients with this newly found mutation can have symptoms triggered by just walking quickly over short distances. Over time these symptoms become permanent. Most ataxic patients also find alcohol worsens their symptoms, and as the same brain cells are attacked by both the alcohol and the genetic defect, it is important to avoid alcohol.”

“This discovery will help thousands of patients world-wide to finally receive an accurate diagnosis of their condition and help them to modify their lifestyle as much as they can”.

Professor Nigel Laing AO Head of Preventive Genetics at the Perkins said new computer programs and DNA sequencing technology helped enable the discovery.

“Bioinformatics tools and long-read DNA sequencing, which have only been available for a relatively short time meant the international team could analyse patient samples from around the world and find a genetic link for the debilitating condition,” he said.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Other Harry Perkins Institute of Medical Research, Web page Photos of patient and researchers
Journal/
conference:
New England Journal of Medicine
Research:Paper
Organisation/s: Harry Perkins Institute of Medical Research
Funder: Supported by the Fondation Groupe Monaco; a grant (PT79418) from the Montreal General Hospital Foundation; a grant (192497) from the Canadian Institutes of Health Research (CIHR); the Care4Rare Canada Consortium, which is funded in part by Genome Canada and the Ontario Genomics Institute (OGI-147), the Canadian Institutes of Health Research, Ontario Research Fund, Genome Quebec, and the Children’s Hospital of Eastern Ontario Foundation; a grant (2R01NS072248-11A1, to Dr. Zuchner) from the National Institutes of Neurological Disorders and Stroke, National Institutes of Health; a Genome Canada Genome Technology Platform award (to Dr. Ragoussis); Canada Foundation for Innovation CGEn (to Dr. Ragoussis); the European Joint Program on Rare Diseases (EJP RD), under the EJP RD COFUND-EJP no. 825575 as part of the PROSPAX consortium, which is funded by the German Research Foundation (to Drs. Synofzik and Schüle); by the Clinician Scientist program PRECISE.net, which is funded by Else Kröner-Fresenius-Stiftung; by the Solve-RD project, which is funded from European Union Horizon 2020 research and innovation program under grant agreement 779257; a grant (01GM1905, to Dr. Schüle) from the Federal Ministry of Education and Research, Germany, through the TreatHSP network; and a grant (2007681, to Dr. Laing) from the Medical Research Future Fund Genomics Future Health Mission. Dr. Pellerin holds a Fellowship award from the CIHR and a Detweiler Travelling Fellowship from the Royal College of Physicians and Surgeons of Canada. Dr. Wilke received support from the Clinician Scientist Program of the Faculty of Medicine, University of Tübingen (grant 480-0-0). Dr. Renaud received a Preston-Robb postdoctoral research fellowship from the Montreal Neurological Hospital and Institute. Ms. Scriba is supported by an Australian Government Research Training Program Scholarship and the Australasian Genomic Technologies Association Ph.D. top-up award. Dr. Jaunmuktane is supported by the Department of Health National Institute for Health and Care Research Biomedical Research Centre funding scheme to University College London Hospitals (UCLH). Dr. Choquet received doctoral awards from the Fonds de Recherche du Québec–Santé and the Fondation du Grand Défi Pierre Lavoie. Dr. Tétreault is supported by a Junior 1 Research Award from the Fonds de Recherche du Québec–Santé. Dr. Boycott is supported by a CIHR Foundation grant (FDN-154279) and a Tier 1 Canada Research Chair in Rare Disease Precision Health. Dr. Dubé holds the Canada Research Chair in precision medicine data analysis. Dr. Houlden is supported by the Wellcome Trust, the U.K. Medical Research Council, and the UCLH Biomedical Research Centre. Dr. Ravenscroft is funded by an Australian National Health and Medical Research Council (NHMRC) Emerging Leader Investigator Grant (APP2007769). Dr. Laing received support from NHMRC fellowship APP1117510. Dr. La Piana received funds from the Canadian Radiological Society. Drs. Schüle, Schöls, and Synofzik are members of the European Reference Network for Rare Neurological Diseases (project 739510).
Media Contact/s
Contact details are only visible to registered journalists.